Progressive burden of myelofibrosis in untreated patients: Assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study

Ruben A. Mesa, Alan Shields, Thomas Hare, Susan Erickson-Viitanen, William Sun, Nicholas J. Sarlis, Victor Sandor, Richard S. Levy, Srdan Verstovsek

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Patient-reported outcomes (PROs) and spleen size in patients not receiving therapy (N=154) in COMFORT-I, a randomized, double-blind study of the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis were evaluated. Baseline PROs indicated considerable disease burden. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 scores, modified Myelofibrosis Symptom Assessment Form v2.0 Total Symptom Score, and Patient Reported Outcome Measurement Information System Fatigue scores worsened from baseline through week 24. At weeks 4 and 24, 18.3 and 40.2% of patients evaluated their condition as having worsened from baseline on the Patient Global Impression of Change questionnaire. Spleen volume and palpable length increased in most patients. These results demonstrate the progressive and debilitating effects of myelofibrosis. The consequences of delayed intervention should be assessed in the management of patients with myelofibrosis and treatment should be considered as clinically indicated for symptomatic relief or splenomegaly control.

Original languageEnglish (US)
Pages (from-to)911-916
Number of pages6
JournalLeukemia Research
Volume37
Issue number8
DOIs
StatePublished - Aug 2013

Fingerprint

Primary Myelofibrosis
Placebos
Spleen
Symptom Assessment
Splenomegaly
Double-Blind Method
Information Systems
Fatigue
Patient Reported Outcome Measures
Therapeutics
Quality of Life
Organizations
Research
Neoplasms

Keywords

  • Fatigue
  • Myelofibrosis
  • Patient-reported outcomes
  • Quality of life
  • Ruxolitinib
  • Splenomegaly

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Progressive burden of myelofibrosis in untreated patients : Assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study. / Mesa, Ruben A.; Shields, Alan; Hare, Thomas; Erickson-Viitanen, Susan; Sun, William; Sarlis, Nicholas J.; Sandor, Victor; Levy, Richard S.; Verstovsek, Srdan.

In: Leukemia Research, Vol. 37, No. 8, 08.2013, p. 911-916.

Research output: Contribution to journalArticle

Mesa, RA, Shields, A, Hare, T, Erickson-Viitanen, S, Sun, W, Sarlis, NJ, Sandor, V, Levy, RS & Verstovsek, S 2013, 'Progressive burden of myelofibrosis in untreated patients: Assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study', Leukemia Research, vol. 37, no. 8, pp. 911-916. https://doi.org/10.1016/j.leukres.2013.04.017
Mesa, Ruben A. ; Shields, Alan ; Hare, Thomas ; Erickson-Viitanen, Susan ; Sun, William ; Sarlis, Nicholas J. ; Sandor, Victor ; Levy, Richard S. ; Verstovsek, Srdan. / Progressive burden of myelofibrosis in untreated patients : Assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study. In: Leukemia Research. 2013 ; Vol. 37, No. 8. pp. 911-916.
@article{51bb6427d47e4e12ace220d5f2e05d08,
title = "Progressive burden of myelofibrosis in untreated patients: Assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study",
abstract = "Patient-reported outcomes (PROs) and spleen size in patients not receiving therapy (N=154) in COMFORT-I, a randomized, double-blind study of the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis were evaluated. Baseline PROs indicated considerable disease burden. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 scores, modified Myelofibrosis Symptom Assessment Form v2.0 Total Symptom Score, and Patient Reported Outcome Measurement Information System Fatigue scores worsened from baseline through week 24. At weeks 4 and 24, 18.3 and 40.2{\%} of patients evaluated their condition as having worsened from baseline on the Patient Global Impression of Change questionnaire. Spleen volume and palpable length increased in most patients. These results demonstrate the progressive and debilitating effects of myelofibrosis. The consequences of delayed intervention should be assessed in the management of patients with myelofibrosis and treatment should be considered as clinically indicated for symptomatic relief or splenomegaly control.",
keywords = "Fatigue, Myelofibrosis, Patient-reported outcomes, Quality of life, Ruxolitinib, Splenomegaly",
author = "Mesa, {Ruben A.} and Alan Shields and Thomas Hare and Susan Erickson-Viitanen and William Sun and Sarlis, {Nicholas J.} and Victor Sandor and Levy, {Richard S.} and Srdan Verstovsek",
year = "2013",
month = "8",
doi = "10.1016/j.leukres.2013.04.017",
language = "English (US)",
volume = "37",
pages = "911--916",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Progressive burden of myelofibrosis in untreated patients

T2 - Assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study

AU - Mesa, Ruben A.

AU - Shields, Alan

AU - Hare, Thomas

AU - Erickson-Viitanen, Susan

AU - Sun, William

AU - Sarlis, Nicholas J.

AU - Sandor, Victor

AU - Levy, Richard S.

AU - Verstovsek, Srdan

PY - 2013/8

Y1 - 2013/8

N2 - Patient-reported outcomes (PROs) and spleen size in patients not receiving therapy (N=154) in COMFORT-I, a randomized, double-blind study of the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis were evaluated. Baseline PROs indicated considerable disease burden. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 scores, modified Myelofibrosis Symptom Assessment Form v2.0 Total Symptom Score, and Patient Reported Outcome Measurement Information System Fatigue scores worsened from baseline through week 24. At weeks 4 and 24, 18.3 and 40.2% of patients evaluated their condition as having worsened from baseline on the Patient Global Impression of Change questionnaire. Spleen volume and palpable length increased in most patients. These results demonstrate the progressive and debilitating effects of myelofibrosis. The consequences of delayed intervention should be assessed in the management of patients with myelofibrosis and treatment should be considered as clinically indicated for symptomatic relief or splenomegaly control.

AB - Patient-reported outcomes (PROs) and spleen size in patients not receiving therapy (N=154) in COMFORT-I, a randomized, double-blind study of the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis were evaluated. Baseline PROs indicated considerable disease burden. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 scores, modified Myelofibrosis Symptom Assessment Form v2.0 Total Symptom Score, and Patient Reported Outcome Measurement Information System Fatigue scores worsened from baseline through week 24. At weeks 4 and 24, 18.3 and 40.2% of patients evaluated their condition as having worsened from baseline on the Patient Global Impression of Change questionnaire. Spleen volume and palpable length increased in most patients. These results demonstrate the progressive and debilitating effects of myelofibrosis. The consequences of delayed intervention should be assessed in the management of patients with myelofibrosis and treatment should be considered as clinically indicated for symptomatic relief or splenomegaly control.

KW - Fatigue

KW - Myelofibrosis

KW - Patient-reported outcomes

KW - Quality of life

KW - Ruxolitinib

KW - Splenomegaly

UR - http://www.scopus.com/inward/record.url?scp=84879781319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879781319&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2013.04.017

DO - 10.1016/j.leukres.2013.04.017

M3 - Article

C2 - 23684482

AN - SCOPUS:84879781319

VL - 37

SP - 911

EP - 916

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 8

ER -